KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Financing Activities (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Cash from Financing Activities for 17 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 10.42% year-over-year to $3.2 million, compared with a TTM value of -$42.4 million through Dec 2025, up 91.95%, and an annual FY2025 reading of -$42.4 million, up 91.95% over the prior year.
  • Cash from Financing Activities was $3.2 million for Q4 2025 at Biomarin Pharmaceutical, up from -$2.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $14.4 million in Q4 2021 and bottomed at -$499.1 million in Q3 2024.
  • Average Cash from Financing Activities over 5 years is -$30.3 million, with a median of -$909500.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities skyrocketed 831.43% in 2022, then crashed 63240.74% in 2024.
  • Year by year, Cash from Financing Activities stood at $14.4 million in 2021, then fell by 24.5% to $10.9 million in 2022, then decreased by 0.27% to $10.8 million in 2023, then tumbled by 73.63% to $2.9 million in 2024, then increased by 10.42% to $3.2 million in 2025.
  • Business Quant data shows Cash from Financing Activities for BMRN at $3.2 million in Q4 2025, -$2.2 million in Q3 2025, and -$4.6 million in Q2 2025.